3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Pancreatic Neoplasms
53
Biliary Tract Neoplasms
23
Nasopharyngeal Carcinoma
22
Carcinoma, Non-Small-Cell Lung
22
Cholangiocarcinoma
21
Urinary Bladder Neoplasms
18
Breast Neoplasms
18
Neoplasm Metastasis
17
Lung Neoplasms
14
Lymphoma, Large B-Cell, Diffuse
13
Colorectal Neoplasms
12
Carcinoma, Transitional Cell
12
Non-Muscle Invasive Bladder Neoplasms
10
Recurrence
8
Ovarian Neoplasms
8
Triple Negative Breast Neoplasms
7
Sarcoma
7
Neoplasms
6
Hodgkin Disease
6
Gallbladder Neoplasms
6
Nasopharyngeal Neoplasms
5
Bile Duct Neoplasms
5
Adenocarcinoma
5
Uterine Cervical Neoplasms
4
Locally Advanced Pancreatic Cancer
4
Endometrial Neoplasms
4
Parkinson Disease 4, Autosomal Dominant Lewy Body
3
Pancreatic Adenocarcinoma
3
Osteosarcoma
3
Lymphoma
3
Interventions
liposomal doxorubicin
1
fludarabine
1
dostarlimab
1
Paclitaxel
1
Gemcitabine
1
Doxorubicin
1
Dexamethasone
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Adenocarcinoma, Clear Cell
×
Gemcitabine
×
Clear all
NCT06023862
2026-05-06
DOVE
Yonsei University
Phase 2
Recruiting
198 enrolled